Protective agent for duck viral hepatitis egg yolk antibody

Abstract

The application provides a protective agent for duck viral hepatitis yolk antibody, and belongs to the field of yolk antibody protective agents, and can solve the technical problems of existing yolk antibody protective agents, such as complex formula, complex preparation process and high cost. The protective agent for duck viral hepatitis yolk antibody comprises the following components in percentage by mass: 1 ‰-1% sterile allantoic fluid and trehalose, wherein the addition amount of trehalose is 2-4 times that of the sterile allantoic fluid. The protective agent for duck viral hepatitis yolk antibody has the characteristics of easy preparation, low cost and convenient use, can significantly improve the long-term stability of the antibody at 2-8 DEG C, and has a good application prospect. The application can be applied to the long-term preservation of yolk antibody.

Description

Technical Field

[0001] This invention belongs to the field of egg yolk antibody protectants, and particularly relates to a protectant for duck viral hepatitis egg yolk antibodies. Background Technology

[0002] Duck viral hepatitis is a common and prevalent disease in duck farming, primarily affecting ducklings aged 7-20 days, with a mortality rate of 50-60%, often causing devastating damage to intensive farms. With the widespread use of antibiotics, pathogens are constantly evolving and mutating. To eliminate the harm caused by antibiotic overuse and reduce and prevent the emergence and spread of drug-resistant strains, the discovery and application of egg yolk antibodies is a major breakthrough in contemporary bioscience. Egg yolk antibodies, due to their advantage of long phylogenetic distance, are more suitable as biological agents, providing a new option for the large-scale development of antibacterial and antiviral prevention and treatment, and have broad application prospects. Duck viral hepatitis egg yolk antibodies are specific antibodies isolated from egg yolk after duck hepatitis vaccination. Clinically, they are often used as a highly effective drug for duck hepatitis, with an efficacy rate exceeding 90%, making them a powerful weapon in the prevention and treatment of clinical duck viral hepatitis.

[0003] Currently, both conventional and refined duck viral hepatitis egg yolk antibodies produced domestically are liquid formulations, which suffer from drawbacks such as low-temperature storage, short shelf life, inconvenient transportation, and unstable titers. Therefore, developing a protective agent to improve the stability of duck viral hepatitis egg yolk antibodies is an effective way to solve these problems. Commonly used egg yolk antibody protective agents include polyhydroxy compounds, sugars, proteins, polymers, amino acids, salts, and surfactants. However, given the characteristics of developing drugs for livestock and poultry farming, the cost of the protective agent cannot be too high, and its application must be simple.

[0004] Therefore, it is particularly urgent and important to develop a new, simple, low-cost, and mass-producible duck viral hepatitis egg yolk antibody protectant. Summary of the Invention

[0005] This invention addresses the technical problems of existing egg yolk antibody protectants, which are characterized by complex formulations, complicated preparation processes, and high costs. It proposes a protectant for duck viral hepatitis egg yolk antibodies that is easy to formulate, low in cost, and convenient to use. This protectant can significantly improve the long-term stability of the antibody at 2–8°C and has good application prospects.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0007] A protective agent for duck viral hepatitis egg yolk antibodies, comprising, by weight and volume percentage, the following components:

[0008] 1‰-1% sterile allantoic fluid and trehalose, wherein the amount of trehalose added is 2-4 times that of the sterile allantoic fluid.

[0009] In one embodiment, the protective agent for duck viral hepatitis egg yolk antibodies comprises, by weight-volume percentage, the following components:

[0010] The sterile allantoic fluid contained 1% and trehalose 2%.

[0011] In one embodiment, the protective agent for duck viral hepatitis egg yolk antibodies comprises, by weight-volume percentage, the following components:

[0012] The sterile allantoic fluid contained 1‰ and 4‰ trehalose.

[0013] In one embodiment, using water for injection as a solvent, the sterile allantoic fluid and trehalose are mixed evenly, and the pH of the solution is adjusted to 7.2-7.4. After sterilization, the protective agent for duck viral hepatitis egg yolk antibodies is obtained.

[0014] In one embodiment, the sterile allantoic fluid is prepared by the following method:

[0015] Chicken embryos are incubated for 15-16 days, and allantoic fluid is collected aseptically. After aseptic filtration, the sterile allantoic fluid is obtained for later use.

[0016] In one embodiment, the protectant for the duck viral hepatitis egg yolk antibody is stored at 2-8°C.

[0017] In one embodiment, the protective agent for the duck viral hepatitis egg yolk antibody has a shelf life of 15 months.

[0018] Compared with the prior art, the advantages and positive effects of the present invention are as follows:

[0019] 1. This invention provides a protectant for duck viral hepatitis egg yolk antibodies, using sterile allantoic fluid and trehalose as the core components of the protectant. By adding the optimal amount of protectant to the duck viral hepatitis egg yolk antibodies, the disadvantages of liquid antibodies being easily inactivated and easily denatured are avoided, making the product quality stable, easy to transport and store for a long time.

[0020] 2. This invention provides a protective agent for duck viral hepatitis egg yolk antibodies. By adding the protective agent to the duck viral hepatitis egg yolk antibodies, the real-time stability of the antibodies at 2-8℃ is significantly improved, and the shelf life can be up to 15 months.

[0021] 3. This invention provides a protective agent for duck viral hepatitis egg yolk antibodies, which is easy to prepare, inexpensive, and convenient to use. It can significantly improve the long-term stability of the antibody at 2-8℃ and has good application prospects. Attached Figure Description

[0022] Figure 1 The results of stability tests on the protective agent for duck viral hepatitis egg yolk antibodies provided in the embodiments of the present invention. Detailed Implementation

[0023] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0024] This invention provides a protective agent for duck viral hepatitis egg yolk antibodies, comprising the following components by weight and volume percentage:

[0025] 1‰-1% sterile allantoic fluid and trehalose, wherein the amount of trehalose added is 2-4 times that of the sterile allantoic fluid.

[0026] The above embodiments of the present invention provide a protectant for duck viral hepatitis egg yolk antibodies. The protectant contains only two components: sterile allantoic fluid and trehalose. The two components work synergistically and enhance each other, achieving the best preservation effect. This solves the technical problems of duck viral hepatitis egg yolk antibodies (liquid form) such as difficulty in low-temperature preservation, short shelf life, inconvenient transportation, and unstable titer.

[0027] In one specific embodiment, the protective agent for duck viral hepatitis egg yolk antibodies comprises, by weight and volume percentage, the following components:

[0028] The sterile allantoic fluid contained 1% and trehalose 2%.

[0029] In one specific embodiment, the protective agent for duck viral hepatitis egg yolk antibodies comprises, by weight and volume percentage, the following components:

[0030] The sterile allantoic fluid contained 1‰ and 4‰ trehalose.

[0031] In one specific embodiment, water for injection is used as a solvent to mix the sterile allantoic fluid and trehalose evenly, and the pH of the solution is adjusted to 7.2-7.4. After sterilization, the protective agent of duck viral hepatitis egg yolk antibody is obtained.

[0032] In the above embodiments, the solution pH can be selected as 7.2, 7.3, 7.4, or any value within the above-defined range that can be selected by those skilled in the art according to actual needs, all of which fall within the protection scope of the present invention.

[0033] In one specific embodiment, the sterile allantoic fluid is prepared by the following method:

[0034] Chicken embryos are incubated for 15-16 days, and allantoic fluid is collected aseptically. After aseptic filtration, the sterile allantoic fluid is obtained for later use.

[0035] In one specific embodiment, the protective agent for the duck viral hepatitis egg yolk antibody is stored at 2-8°C.

[0036] In one specific embodiment, the protective agent for duck viral hepatitis egg yolk antibodies has a shelf life of 15 months.

[0037] In the above embodiments, when the protective agent described in the above embodiments is added to the duck viral hepatitis egg yolk antibody, the neutralizing antibody titer of the egg yolk antibody remains at 1:900 after being stored at 8 degrees Celsius for 0 months, 3 months, 6 months, 9 months, 12 months and 15 months, and the antibody titer does not change.

[0038] To provide a clearer and more detailed description of the protective agent for duck viral hepatitis egg yolk antibodies provided in the embodiments of the present invention, specific embodiments will be described below.

[0039] Example 1

[0040] This embodiment provides a protective agent for duck viral hepatitis egg yolk antibodies, specifically:

[0041] The protective agent for duck viral hepatitis egg yolk antibodies, by weight-volume percentage (g / ml), comprises the following components: 1% sterile allantoic fluid and 2% trehalose; using water for injection as a solvent, the above components are mixed evenly and the pH is adjusted to 7.2. After sterilization, the protective agent for duck viral hepatitis egg yolk antibodies can be prepared and stored at 2-8℃ for later use.

[0042] The above-mentioned protective agent for egg yolk antibodies was added to commercially available duck viral hepatitis egg yolk antibodies, and a stability test was conducted, while the test results were recorded.

[0043] Example 2

[0044] This embodiment provides a protective agent for duck viral hepatitis egg yolk antibodies, specifically:

[0045] The protective agent for duck viral hepatitis egg yolk antibodies, by weight-volume percentage (g / ml), comprises the following components: 1‰ of sterile allantoic fluid and 4‰ of trehalose; using water for injection as a solvent, the above components are mixed evenly and the pH is adjusted to 7.4. After sterilization, the protective agent for duck viral hepatitis egg yolk antibodies can be prepared and stored at 2-8℃ for later use.

[0046] The protective agent of the above-mentioned egg yolk antibody was added to the commercially available duck viral hepatitis egg yolk antibody (same as in Example 1), and a stability test was conducted, while the test results were recorded.

[0047] Comparative Example

[0048] This comparative example uses the same commercially available duck viral hepatitis egg yolk antibody as in Examples 1-2, without adding any protective agent, and performs stability tests on it, while recording the test results.

[0049] Stability test

[0050] This experiment was conducted under storage conditions of 2-8℃. The real-time stability of egg yolk antibodies preserved with the antibody protectants of Examples 1 and 2 and the egg yolk antibodies without protectants described in the comparative example were monitored. The specific operating methods are as follows:

[0051] Egg yolk antibodies preserved with the antibody protectants of Examples 1 and 2, as well as egg yolk antibodies without protectants in the comparative example, were stored at 8°C for 3 months, 6 months, 9 months, 12 months, and 15 months, respectively. The titers of egg yolk neutralizing antibodies against duck viral hepatitis were then measured, and the results are shown in Table 1.

[0052] Table 1. Results of stability tests

[0053]

[0054]

[0055] Analysis of the above experimental results shows that when no protective agent was added to the duck viral hepatitis egg yolk antibody, the neutralizing antibody titers after storage at 8 degrees Celsius for 0, 3, 6, 9, 12, and 15 months were 1:900, 1:900, 1:800, 1:800, 1:600, and 1:500, respectively. The antibody titer decreased significantly with prolonged storage time. However, when the protective agent shown in Examples 1-2 was added to the duck viral hepatitis egg yolk antibody, the neutralizing antibody titer remained at 1:900 after storage at 8 degrees Celsius for 0, 3, 6, 9, 12, and 15 months, with no change in antibody titer. Therefore, it can be seen that adding the protective agent provided by this invention to duck viral hepatitis egg yolk antibody can significantly improve the real-time stability of egg yolk antibody at 2-8°C, and the shelf life can be up to 15 months. This solves the technical problems of duck viral hepatitis egg yolk antibody (liquid form) such as difficulty in low-temperature preservation, short shelf life, inconvenient transportation, and unstable titer.

Claims

1. A protective agent for duck viral hepatitis egg yolk antibodies, characterized in that, Based on mass-volume ratio, it includes the following components: Trehalose and 1‰-1% sterile allantoic fluid, wherein the amount of trehalose added is 2-4 times that of the sterile allantoic fluid; The sterile allantoic fluid was prepared by the following method: Chicken embryos are incubated for 15-16 days, and allantoic fluid is collected aseptically. After aseptic filtration, the sterile allantoic fluid is obtained for later use.

2. The protective agent for duck viral hepatitis egg yolk antibodies according to claim 1, characterized in that, Based on mass-volume ratio, it includes the following components: The sterile allantoic fluid was 1% and the trehalose content was 2%.

3. The protective agent for duck viral hepatitis egg yolk antibodies according to claim 1, characterized in that, Based on mass-volume ratio, it includes the following components: The sterile allantoic fluid was 1‰ and the trehalose was 4‰.

4. The protective agent for duck viral hepatitis egg yolk antibodies according to any one of claims 1-3, characterized in that, Using water for injection as a solvent, the sterile allantoic fluid and trehalose were mixed evenly, and the pH of the solution was adjusted to 7.2-7.

4. After sterilization, the protective agent for duck viral hepatitis egg yolk antibodies was obtained.

Images